Microbial Sensitivity Tests
Research News and Information

Sunday, November 22, 2009

Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States.

13 Nov 2009 BACKGROUND: The Enterococcus faecium genogroup, referred to as clonal complex 17 (CC17), seems to possess multiple determinants that increase its ability to survive and cause disease in nosocomial environments. METHODS: Using 53 clinical and ... Read more...

Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors.

18 Oct 2009 Extended-spectrum beta-lactamases (ESBLs) are derivatives of enzymes such as SHV-1 and TEM-1 that have undergone site-specific mutations that enable them to hydrolyze, and thus inactivate, oxyimino-cephalosporins, such as cefotaxime and ceftazidime. ... Read more...

Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

13 Oct 2009 BACKGROUND: Most cases of reduced vancomycin susceptibility in Staphylococcus aureus reported in the literature have been in methicillin-resistant strains. We report the development of reduced vancomycin susceptibility in a series of clonally ... Read more...

Latest indexed articles for 'Microbial Sensitivity Tests'

These are the very latest articles for this heading:

• Analysis of clonality and antibiotic resistance among early clinical isolates of Enterococcus faecium in the United States. 13 Nov 2009
• Why the extended-spectrum beta-lactamases SHV-2 and SHV-5 are "hypersusceptible" to mechanism-based inhibitors. 18 Oct 2009
• Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. 13 Oct 2009
• Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. 12 Oct 2009
• Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study. 6 Oct 2009
• Nitazoxanide kills replicating and nonreplicating Mycobacterium tuberculosis and evades resistance. 6 Oct 2009
• Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent. 3 Oct 2009
• Antimicrobial properties of hemokinin-1 against strains of Pseudomonas aeruginosa. 30 Sep 2009
• Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis. 29 Sep 2009
• Methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii on computer interface surfaces of hospital wards and association with clinical isolates. 29 Sep 2009
• Defining wound microbial flora: molecular microbiology opening new horizons. 29 Sep 2009
• Characterization of class 1 integrons and gene cassettes in clinical isolates of Klebsiella pneumoniae from Taiwan. 29 Sep 2009
• Impact of human serum albumin on oritavancin in vitro activity against Staphylococcus aureus. 29 Sep 2009
• Predominance of CTX-M-type extended-spectrum beta-lactamase genes among enterobacterial isolates from outpatients in Brazil. 29 Sep 2009
• In vitro activity of daptomycin against Staphylococcus aureus and vancomycin-resistant Enterococcus faecium isolates associated with skin and soft tissue infections: first results from India. 29 Sep 2009
• Cost analysis and antimicrobial susceptibility testing comparing the E test and the agar dilution method in Campylobacter jejuni and Campylobacter coli. 29 Sep 2009
• Combination of IMP-4 metallo-beta-lactamase production and porin deficiency causes carbapenem resistance in a Klebsiella oxytoca clinical isolate. 29 Sep 2009
• Antimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007-2008). 29 Sep 2009
• Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. 29 Sep 2009
• Sensitivity to azoxystrobin in Didymella bryoniae isolates collected before and after field use of strobilurin fungicides. 29 Sep 2009

See a longer list of these articles.

Technical information about 'Microbial Sensitivity Tests'

Definition: Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses).

Descriptor UI: D008826

Alternative terms: Microbial Sensitivity Tests; Microbial Sensitivity Test; Sensitivity Test, Microbial; Sensitivity Tests, Microbial; Test, Microbial Sensitivity; Tests, Microbial Sensitivity; Drug Sensitivity Assay, Microbial; Virus Drug Sensitivity Tests; Viral Drug Sensitivity Tests; Fungus Drug Sensitivity Tests; Fungal Drug Sensitivity Tests; Minimum Inhibitory Concentration; Concentration, Minimum Inhibitory; Concentrations, Minimum Inhibitory; Inhibitory Concentration, Minimum; Inhibitory Concentrations, Minimum; Minimum Inhibitory Concentrations; Antibiogram; Antibiograms; Bacterial Sensitivity Tests; Tests, Bacterial Sensitivity; Sensitivity Tests, Bacterial; Test, Bacterial Sensitivity; Bacterial Sensitivity Test; Sensitivity Test, Bacterial;

Related Mesh Headings: Drug Resistance, Microbial; Inhibitory Concentration 50; Parasitic Sensitivity Tests;

Allowable Qualifiers: history; instrumentation; methods; standards; trends; utilization; veterinary; statistics & numerical data; ethics; classification; economics;

Tree Number: E05.200.875.595; E05.337.550.400;

History Note: 70

Technical Notes: IM when general; NIM when with specific drug (IM) & specific micro-organisms (IM); note X ref MINIMUM INHIBITORY CONCENTRATION but bactericidal eff of an antimicrobial drug using patient's blood (= SERUM BACTERICIDAL TEST + specific drug); PARASITIC SENSITIVITY TESTS is also available